Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Inhibition of peptidyl-arginine deiminases reverses protein-hypercitrullination and disease in mouse models of multiple sclerosis.

Moscarello MA, Lei H, Mastronardi FG, Winer S, Tsui H, Li Z, Ackerley C, Zhang L, Raijmakers R, Wood DD.

Dis Model Mech. 2013 Mar;6(2):467-78. doi: 10.1242/dmm.010520. Epub 2012 Nov 1.

2.

A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo.

Ni YG, Di Marco S, Condra JH, Peterson LB, Wang W, Wang F, Pandit S, Hammond HA, Rosa R, Cummings RT, Wood DD, Liu X, Bottomley MJ, Shen X, Cubbon RM, Wang SP, Johns DG, Volpari C, Hamuro L, Chin J, Huang L, Zhao JZ, Vitelli S, Haytko P, Wisniewski D, Mitnaul LJ, Sparrow CP, Hubbard B, CarfĂ­ A, Sitlani A.

J Lipid Res. 2011 Jan;52(1):78-86. doi: 10.1194/jlr.M011445. Epub 2010 Oct 19.

3.

A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.

Ni YG, Condra JH, Orsatti L, Shen X, Di Marco S, Pandit S, Bottomley MJ, Ruggeri L, Cummings RT, Cubbon RM, Santoro JC, Ehrhardt A, Lewis D, Fisher TS, Ha S, Njimoluh L, Wood DD, Hammond HA, Wisniewski D, Volpari C, Noto A, Lo Surdo P, Hubbard B, CarfĂ­ A, Sitlani A.

J Biol Chem. 2010 Apr 23;285(17):12882-91. doi: 10.1074/jbc.M110.113035. Epub 2010 Feb 19.

4.

Myelin localization of peptidylarginine deiminases 2 and 4: comparison of PAD2 and PAD4 activities.

Wood DD, Ackerley CA, Brand Bv, Zhang L, Raijmakers R, Mastronardi FG, Moscarello MA.

Lab Invest. 2008 Apr;88(4):354-64. doi: 10.1038/labinvest.3700748. Epub 2008 Jan 28.

5.

Synergy between paclitaxel plus an exogenous methyl donor in the suppression of murine demyelinating diseases.

Mastronardi FG, Tsui H, Winer S, Wood DD, Selvanantham T, Galligan C, Fish EN, Dosch HM, Moscarello MA.

Mult Scler. 2007 Jun;13(5):596-609. Epub 2007 Feb 9.

PMID:
17548438
6.

Peptidyl argininedeiminase 2 CpG island in multiple sclerosis white matter is hypomethylated.

Mastronardi FG, Noor A, Wood DD, Paton T, Moscarello MA.

J Neurosci Res. 2007 Jul;85(9):2006-16.

PMID:
17469138
7.

Increased citrullination of histone H3 in multiple sclerosis brain and animal models of demyelination: a role for tumor necrosis factor-induced peptidylarginine deiminase 4 translocation.

Mastronardi FG, Wood DD, Mei J, Raijmakers R, Tseveleki V, Dosch HM, Probert L, Casaccia-Bonnefil P, Moscarello MA.

J Neurosci. 2006 Nov 1;26(44):11387-96.

8.

The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis.

Moscarello MA, Mastronardi FG, Wood DD.

Neurochem Res. 2007 Feb;32(2):251-6. Epub 2006 Sep 22. Review.

9.

Autocatalytic cleavage of myelin basic protein: an alternative to molecular mimicry.

D'Souza CA, Wood DD, She YM, Moscarello MA.

Biochemistry. 2005 Sep 27;44(38):12905-13.

PMID:
16171406
10.

Multiple sclerosis: an important role for post-translational modifications of myelin basic protein in pathogenesis.

Kim JK, Mastronardi FG, Wood DD, Lubman DM, Zand R, Moscarello MA.

Mol Cell Proteomics. 2003 Jul;2(7):453-62. Epub 2003 Jun 25.

11.

Expression and properties of the recombinant murine Golli-myelin basic protein isoform J37.

Kaur J, Libich DS, Campagnoni CW, Wood DD, Moscarello MA, Campagnoni AT, Harauz G.

J Neurosci Res. 2003 Mar 15;71(6):777-84.

PMID:
12605403
12.

Primary structure of equine myelin basic protein by mass spectrometry.

Wood DD, She YM, Freer AD, Harauz G, Moscarello MA.

Arch Biochem Biophys. 2002 Sep 1;405(1):137-46.

PMID:
12176067
13.

An Arg/Lys-->Gln mutant of recombinant murine myelin basic protein as a mimic of the deiminated form implicated in multiple sclerosis.

Bates IR, Libich DS, Wood DD, Moscarello MA, Harauz G.

Protein Expr Purif. 2002 Jul;25(2):330-41.

PMID:
12135568
14.

Peptidylarginine deiminase: a candidate factor in demyelinating disease.

Moscarello MA, Pritzker L, Mastronardi FG, Wood DD.

J Neurochem. 2002 Apr;81(2):335-43.

15.

Paclitaxel (Taxol) attenuates clinical disease in a spontaneously demyelinating transgenic mouse and induces remyelination.

Moscarello MA, Mak B, Nguyen TA, Wood DD, Mastronardi F, Ludwin SK.

Mult Scler. 2002 Apr;8(2):130-8.

PMID:
11990870
16.

The effects of deimination of myelin basic protein on structures formed by its interaction with phosphoinositide-containing lipid monolayers.

Ishiyama N, Bates IR, Hill CM, Wood DD, Matharu P, Viner NJ, Moscarello MA, Harauz G.

J Struct Biol. 2001 Oct;136(1):30-45.

PMID:
11858705
17.

T cells of multiple sclerosis patients target a common environmental peptide that causes encephalitis in mice.

Winer S, Astsaturov I, Cheung RK, Schrade K, Gunaratnam L, Wood DD, Moscarello MA, O'Connor P, McKerlie C, Becker DJ, Dosch HM.

J Immunol. 2001 Apr 1;166(7):4751-6.

18.

Characterization of a recombinant murine 18.5-kDa myelin basic protein.

Bates IR, Matharu P, Ishiyama N, Rochon D, Wood DD, Polverini E, Moscarello MA, Viner NJ, Harauz G.

Protein Expr Purif. 2000 Nov;20(2):285-99.

PMID:
11049752
19.

Cryoelectron microscopy of protein-lipid complexes of human myelin basic protein charge isomers differing in degree of citrullination.

Beniac DR, Wood DD, Palaniyar N, Ottensmeyer FP, Moscarello MA, Harauz G.

J Struct Biol. 2000 Feb;129(1):80-95.

PMID:
10675299
20.

Highly deiminated isoform of myelin basic protein from multiple sclerosis brain causes fragmentation of lipid vesicles.

Boggs JM, Rangaraj G, Koshy KM, Ackerley C, Wood DD, Moscarello MA.

J Neurosci Res. 1999 Aug 15;57(4):529-35.

PMID:
10440902
21.

Marburg's variant of multiple sclerosis correlates with a less compact structure of myelin basic protein.

Beniac DR, Wood DD, Palaniyar N, Ottensmeyer FP, Moscarello MA, Harauz G.

Mol Cell Biol Res Commun. 1999 Apr;1(1):48-51.

PMID:
10329477
22.

Human proteolipid protein (PLP) mediates winding and adhesion of phospholipid membranes but prevents their fusion.

Palaniyar N, Semotok JL, Wood DD, Moscarello MA, Harauz G.

Biochim Biophys Acta. 1998 Dec 9;1415(1):85-100.

23.

Minimizing fatigue during repetitive jobs: optimal work-rest schedules.

Wood DD, Fisher DL, Andres RO.

Hum Factors. 1997 Mar;39(1):83-101.

PMID:
9302881
24.

Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein.

Wood DD, Bilbao JM, O'Connors P, Moscarello MA.

Ann Neurol. 1996 Jul;40(1):18-24.

PMID:
8687186
25.

Participation of acetylpseudouridine in the synthesis of a peptide bond in vitro.

Wood DD, Pang H, Hempel A, Camerman N, Lane BG, Moscarello MA.

J Biol Chem. 1995 Sep 8;270(36):21040-4.

26.
27.

Myelin in multiple sclerosis is developmentally immature.

Moscarello MA, Wood DD, Ackerley C, Boulias C.

J Clin Invest. 1994 Jul;94(1):146-54.

28.

Immunological analysis of the amino terminal and the C8 isomer of human myelin basic protein.

Zhou SR, Whitaker JN, Wood DD, Moscarello MA.

J Neuroimmunol. 1993 Jul;46(1-2):91-6.

PMID:
7689598
29.

The N terminus of human myelin basic protein consists of C2, C4, C6, and C8 alkyl carboxylic acids.

Moscarello MA, Pang H, Pace-Asciak CR, Wood DD.

J Biol Chem. 1992 May 15;267(14):9779-82.

30.

An immunochemical comparison of human myelin basic protein and its modified, citrullinated form, C8.

Whitaker JN, Kirk KA, Herman PK, Zhou SR, Goodin RR, Moscarello MA, Wood DD.

J Neuroimmunol. 1992 Feb;36(2-3):135-46.

PMID:
1370666
31.

A hydroxyproline-containing protein from shark brain that is related to myelin basic protein.

Wood DD, McLaurin J, Moscarello MA.

J Neurochem. 1990 Nov;55(5):1697-702.

PMID:
1698931
32.

Glycolipids as host resistance stimulators.

Ponpipom MM, Hagmann WK, O'Grady LA, Jackson JJ, Wood DD, Zweerink HJ.

J Med Chem. 1990 Feb;33(2):861-7.

PMID:
2299649
33.

Steroidal glycolipid, L-644,257, is a potent enhancer of nonspecific host resistance.

Hagmann WK, Ponpipom MM, Jackson JJ, Wood DD, Boltz RC Jr, Zweerink HJ.

Int J Immunopharmacol. 1990;12(2):241-6.

PMID:
2329016
34.

Interaction of glycosylated human myelin basic protein with lipid bilayers.

Persaud R, Boggs JM, Wood DD, Moscarello MA.

Biochemistry. 1989 May 16;28(10):4209-16.

PMID:
2475162
35.
36.

Prostaglandins in inflammatory bone pathology: mechanism and therapeutic benefit of etodolac.

Hayward MA, Howard GA, Neuman RG, Wood DD, Weichman BM, Van Sickle DC.

Agents Actions. 1989 Mar;26(3-4):310-8.

PMID:
2525314
37.
38.

The glycosylation of human myelin basic protein at threonines 95 and 98 occurs sequentially.

Persaud R, Fraser P, Wood DD, Moscarello MA.

Biochim Biophys Acta. 1988 Sep 8;966(3):357-61.

PMID:
2458139
39.

An ELISA for PGE2 utilizing monoclonal antibody.

Neuman RG, Korn JH, Lally ET, Wood DD, Kimball ES.

J Immunoassay. 1988;9(2):159-77.

PMID:
3163699
40.

Inhibition of prostaglandin biosynthesis by etodolac. I. Selective activities in arthritis.

Neuman RG, Wilson BD, Barkley M, Kimball ES, Weichman BM, Wood DD.

Agents Actions. 1987 Jun;21(1-2):160-6.

PMID:
2957897
41.

Serological characterization of acidic (pI 5.5) and neutral (pI 7.1) forms of 17kD and 35kD interleukin-1.

Kimball ES, Simon PL, Saklatvala J, Metzner R, Wood DD.

Lymphokine Res. 1986 Spring;5(2):119-25.

PMID:
3486329
43.

Functional consequences of perceived interleukin deficiencies? Analysis employing NZB x C58 recombinant inbred mice.

Bocchieri MH, Smith JB Jr, Smith JB, Staruch MJ, Wood DD.

Clin Exp Immunol. 1985 Dec;62(3):622-9.

44.

Release of interleukin-1 from human synovial tissue in vitro.

Wood DD, Ihrie EJ, Hamerman D.

Arthritis Rheum. 1985 Aug;28(8):853-62.

PMID:
3875350
45.
46.

The role of charge microheterogeneity of human myelin basic protein in the formation of phosphatidylglycerol multilayers.

Brady GW, Fein DB, Wood DD, Moscarello MA.

Biochem Biophys Res Commun. 1985 Feb 15;126(3):1161-5.

PMID:
2579646
47.

Reduction of serum Interleukin-1-like activity after treatment with dexamethasone.

Staruch MJ, Wood DD.

J Leukoc Biol. 1985 Feb;37(2):193-207.

PMID:
3871468
48.

The four biochemically distinct species of human interleukin 1 all exhibit similar biologic activities.

Wood DD, Bayne EK, Goldring MB, Gowen M, Hamerman D, Humes JL, Ihrie EJ, Lipsky PE, Staruch MJ.

J Immunol. 1985 Feb;134(2):895-903.

PMID:
3871220
49.

Biochemical heterogeneity of human interleukin-1.

Ihrie EJ, Wood DD.

Lymphokine Res. 1985 Summer;4(3):169-81.

PMID:
3875764
50.

Contamination of commercial leukocyte-derived human interleukin 2 with interleukin 1.

Ihrie EJ, Wood DD.

Lymphokine Res. 1985 Winter;4(1):39-42.

PMID:
3872384

Supplemental Content

Support Center